Day 1

ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access

solaci
solaci
617
0

Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the safety and efficacy of two vascular closure devices (FemoSeal and ExoSeal) versus manual compression. The work included 4524 patients undergoing diagnostic coronary angiography using a 6 Fr introducer, randomized 1: 1: 1 to FemoSeal, ExoSeal or manual compression. Both closures were not inferior to the manual compression in terms of vascular access complications. The FemoSeal trended lower vascular complications and length of the hemostasis than ExoSeal. 

5_stefanie_schulz

Stefanie Schulz
2014-09-14

Original title: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access.

Previous article
CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection
Next article
CTO-IVUS: IVUS clinical impact in total occlusions with 2nd generation DES
solaci
solaci

More articles by this author

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

solaci - 0
The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the...

PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients

solaci - 0
This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality,...

CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients

solaci - 0
This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.  The...

US CoreValve: Cost effectiveness of transcatheter replacement versus surgical replacement in high-risk patients

solaci - 0
Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection

The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of...
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Dr. Omar Tupayachi - 0
Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

Dr. Omar Tupayachi - 0
The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Dr. Juan Manuel Pérez - 0
Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...